

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Empower Clinics Inc. (the "Issuer").

Trading Symbol: EPW

Number of Outstanding Listed Securities: 103,471,756

Date: May 6, 2024

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued to make progress on business development activities including its research and clinical trials initiatives under its subsidiary EPW Curesearch LLC generating new revenue commencing November 2023. The Issuer is expanding its reach to other new U.S. markets pursuing additional new principal investigators and new clinical trial opportunities.

The Company announced that the British Columbia Securities Commission (the “BCSC”) has issued an order dated April 2, 2024 (the “Partial Revocation Order”) partially revoking the failure-to-file cease trade order (the “FFCTO”) which was issued against the Company by the BCSC and the Ontario Securities Commission (the “OSC”) on August 14, 2023 due to the Company’s failure to file annual audited financial statements, management’s discussion and analysis and certifications of annual filings for the fiscal year ended March 31, 2023.

2. Provide a general overview and discussion of the activities of management.

Management is focused on key accounting and audit requirements, working toward completion of outstanding filings returning to full trading status, along with business development activity under EPW Curesearch LLC. and the implementation on its first awarded clinical trial.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law. **N/A**
4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned. **N/A**
5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.
6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced. **N/A**
7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship. **N/A**
8. Describe the acquisition of new customers or loss of customers. **N/A**
9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks. **N/A**
10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs. **N/A**
11. Report on any labour disputes and resolutions of those disputes if applicable. **The Issuer is responding to an employment wage claim in B.C. related to Medi+Sure Canada Inc.**
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

The Issuer is party to a matter in Dallas, TX courts with a former employee Yoshi Tyler. On April 17, 2024 a final judgment was entered in the matter in favour of the Plaintiff against Empower Clinics Inc. and Empower Healthcare Assets Inc. The judgment fully disposes of all claims and all parties and is appealable. The Issuer is party to a claim and counterclaims with Mario Cortis and Roberto Cortis. The Issuer received notice of a response and counterclaim by Roberto Cortis. The Issuer is seeking advice on how to proceed next. No further activity on the matter has taken place.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness. **N/A**
14. Provide details of any securities issued and options or warrants granted. **N/A**
- (1) State aggregate proceeds and intended allocation of proceeds.*
15. Provide details of any loans to or by Related Persons. **N/A**
16. Provide details of any changes in directors, officers or committee members. **N/A**
17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends. **N/A**


Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated May 6, 2024

Steven McAuley
Name of Director or Senior
Officer


Signature
CEO
Official Capacity

Issuer Details Name of Issuer Empower Clinics Inc.	For Month End April 30 th , 2024	Date of Report YY/MM/D 24/05/06
Issuer Address 505-1771 Robson Street		
City/Province/Postal Code Vancouver, BC V6G 1C9	Issuer Fax No. ()	Issuer Telephone No. 1-855-855-9058
Contact Name Steven McAuley	Contact Position CEO	Contact Telephone No. 1- 855-855-9058
Contact Email Address info@empowerclinics.com	Web Site Address https://www.empowerclinics.com	